Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE: EVMN ) with a Overweight and lowers the price target from $55 to $26.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.